5. The method of claim 1, wherein the antagonist is a peptide corresponding to the LRP-6 binding site of Dkk-1.
6. The method of claim 1, wherein the antagonist is peptide A as set forth in SEQ ID NO:11.
7. The method of claim 1, wherein the antagonist is an antibody that specifically binds Dkk-1.
8. A method of treating an osteolytic lesion in a mammal comprising administering to a mammal in need thereof an effective amount of a GSK3β inhibitor, wherein said GSK3β inhibitor mimics positive Wnt signaling.
9. The method of claim 8, wherein the GSK3β inhibitor is lithium chloride.
10. A method of enhancing osteogenesis in a mammal comprising administering to a mammal in need thereof an effective amount of a Dkk-1 antagonist, wherein said Dkk-1 antagonist inhibits Dkk-1 activity on the Wnt signaling pathway.
11. The method of claim 10, wherein said mammal is a human.
12. The method of claim 10, wherein the antagonist is directed to human Dkk-1.
13. The method of claim 10, wherein the antagonist comprises a peptide corresponding to the LRP-6 binding site of Dkk-1.
14. The method of claim 10, wherein the antagonist is peptide A as set forth in SEQ ID NO:11.
15. The method of claim 10, wherein the antagonist is an antibody that specifically binds Dkk-1.
http://www.freepatentsonline.com/y2005/0084494.html
Interesting..............
|
Thread view
Order